| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Technical Briefs |
(1 Department of Cardiovascular Diseases, Katholieke Universiteit Leuven, Leuven, Belgium;2 Laboratory for Clinical Biochemistry Research and Department of Pathology, University of Vermont College of Medicine, Burlington, VT;
aaddress correspondence to this author at: Atherosclerosis and Metabolism Unit, Department of Cardiovascular Diseases, Katholieke Universiteit Leuven, Herestraat 49, PB 705, B-3000 Leuven, Belgium; fax 32-16-347114, e-mail paul.holvoet{at}med.kuleuven.be)
Abstract
Background: Oxidized LDL (ox-LDL) plays an important role in the pathogenesis of coronary heart disease (CHD). Several tests for circulating ox-LDL have been published. We believe it is critical to carefully evaluate these assays because small differences in performance may have profound effects when results are compared; we therefore compared the analytical and clinical performances of 2 assays: one developed in our laboratory and a commercial assay (Mercodia) that uses the same monoclonal antibody (4E6).
Methods: We determined the variance of ox-LDL in both tests, including its longitudinal stability (n = 225; 3 time points per person) and its diagnostic accuracy, by ROC analysis of 95 consecutive CHD patients and 20 controls.
Results: The between-person variability was 77% for the in-house assay (with the remaining 23% being within-person and analytical variance) and 74% for the commercial assay. For comparison, previously reported values were 66% for high-sensitivity C-reactive protein and 82% for total cholesterol. The areas under the curves for CHD in the 2 assays were identical (0.85). The odds ratios (logistic regression) for CHD among persons with high ox-LDL (
15 mg/L) compared with persons with low ox-LDL were not different: 4.3 (95% confidence interval, 1.4–12) for the in-house assay and 3.3 (1.1–10) for the commercial assay.
Conclusions: The longitudinal stability of ox-LDL, as assessed by multiple measures in people over time, is similar to that of total cholesterol and high-sensitivity C-reactive protein. Both assays tested similarly distinguish between healthy controls and CHD patients.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  D. De Keyzer, S.-A. Karabina, W. Wei, B. Geeraert, D. Stengel, J. Marsillach, J. Camps, P. Holvoet, and E. Ninio Increased PAFAH and Oxidized Lipids Are Associated With Inflammation and Atherosclerosis in Hypercholesterolemic Pigs Arterioscler Thromb Vasc Biol, December 1, 2009; 29(12): 2041 - 2046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Park, M. Gross, D.-H. Lee, P. Holvoet, J. H. Himes, J. M. Shikany, and D. R. Jacobs Jr. Oxidative Stress and Insulin Resistance: The Coronary Artery Risk Development in Young Adults study Diabetes Care, July 1, 2009; 32(7): 1302 - 1307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Meier, D. Golshayan, E. Blanc, M. Pascual, and M. Burnier Oxidized LDL Modulates Apoptosis of Regulatory T Cells in Patients with ESRD J. Am. Soc. Nephrol., June 1, 2009; 20(6): 1368 - 1384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Rietzschel, M. Langlois, M. L. De Buyzere, P. Segers, D. De Bacquer, S. Bekaert, L. Cooman, P. Van Oostveldt, P. Verdonck, G. G. De Backer, et al. Oxidized Low-Density Lipoprotein Cholesterol Is Associated With Decreases in Cardiac Function Independent of Vascular Alterations Hypertension, September 1, 2008; 52(3): 535 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Holvoet, D.-H. Lee, M. Steffes, M. Gross, and D. R. Jacobs Jr Association Between Circulating Oxidized Low-Density Lipoprotein and Incidence of the Metabolic Syndrome JAMA, May 21, 2008; 299(19): 2287 - 2293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Gaubatz, B. K. Gillard, J. B. Massey, R. C. Hoogeveen, M. Huang, E. E. Lloyd, J. L. Raya, C.-y. Yang, and H. J. Pownall Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A2 J. Lipid Res., February 1, 2007; 48(2): 348 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Meier, F. Spertini, E. Blanc, and M. Burnier Oxidized Low-Density Lipoproteins Activate CD4+ T Cell Apoptosis in Patients with End-Stage Renal Disease through Fas Engagement J. Am. Soc. Nephrol., January 1, 2007; 18(1): 331 - 342. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
